MetaCap

Ironwood Pharmaceuticals Inc. Class A (IRWD)

NASDAQ: IRWDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.70-0.01 (-0.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRWD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$778.09M
52-week range
2.95 – 5.78
Day range
4.65 – 4.87
Volume / Avg
3.02M / 2.15M
Beta
—

52-week range

$2.95$5.78

IRWD stock today

Ironwood Pharmaceuticals (IRWD) closed at $4.70 on Nov 20, down 0.21% (-$0.01), versus the S&P 500's 3.70% decline. At this level, IRWD sits in the middle of its 52-week range of $2.95 to $5.78: 18.7% below the high, set on Jan 2, 2026 and 59.3% above the low. IRWD is up 39.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.7%.

Ironwood Pharmaceuticals trades at 5.2x its trailing twelve-month earnings per share of $0.90. Its forward P/E of 3.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Ironwood Pharmaceuticals

Company profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thomas A. McCourt
Headquarters
Boston, MA
Employees
100
IPO year
2010

Financial highlights

Full financials

In fiscal 2025, Ironwood Pharmaceuticals generated $296.2 million in revenue, down 15.7% from fiscal 2024, its first annual decline since 2024. Net income was $24.0 million (+2629.2% year over year), for a net margin of 8.1% versus a median of 27.3% in the prior 5 years. Operating margin was 33.3%.

Ironwood Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$296.15M$351.41M$442.74M$410.60M$413.75M
Growth-15.72%-20.63%+7.83%-0.76%+6.22%
Net income$24.02M$880.00K$-1.00B$175.06M$528.45M
EPS (diluted)$0.15$0.01$-6.45$0.96$3.21

Analyst forecast

Forecast

Consensus (4 analysts)

buy

Avg. price target

$6.18+31.49%

  • Strong buy 1
  • Buy 1
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $3.70High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.36 vs $0.30
Surprise
+20.00%

IRWD news

All IRWD news

Ironwood Pharmaceuticals peers

Health Care sector
IRWD peer companies
CompanyPrice% ChgMarket capCompare
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs IRWD
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs IRWD
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs IRWD
VSTMVerastem Inc.6.33-7.73%$797.67Mvs IRWD
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs IRWD
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs IRWD
IVAInventiva S.A. American Depository Shares3.14-8.99%$750.78Mvs IRWD
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs IRWD

Indexes, lists and sector

Ironwood Pharmaceuticals stock FAQ

What is Ironwood Pharmaceuticals's stock price today?

IRWD last traded at $4.70 as of Nov 20, 4:00 PM EST, down 0.21% on the day. Prices are delayed at least 15 minutes.

Does Ironwood Pharmaceuticals pay a dividend?

No. Ironwood Pharmaceuticals does not currently pay a regular cash dividend.

What is IRWD's P/E ratio?

IRWD trades at a trailing P/E ratio of 5.22 and a forward P/E of 3.00.

Who is Ironwood Pharmaceuticals's CEO?

Mr. Thomas A. McCourt is the chief executive officer of Ironwood Pharmaceuticals Inc. Class A, which has about 100 employees.

Has IRWD ever split its stock?

Yes. The most recent IRWD stock split was a 1194-for-1000 split on Apr 2, 2019.

What is the IRWD 52-week high?

The 52-week high for IRWD is $5.78 and the 52-week low is $2.95. The stock is currently 18.7% below its high.

Compare IRWD